Rising Need for Outsourced Peptide API Manufacturing will increase the Overall Market's Sales and will reach around USD 2,659.8 Mn in 2023

According to Precision Business Insights (PBI), the latest report, the Peptide API CMO Market was valued at USD 1,756.0 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2029. The demand for peptide generic APIs and peptide NCEs among peptide API CMOs is expected to continue growing at a significant pace, driven by factors such as the expanding pipeline of peptide drugs, advancements in drug delivery technology, and the increasing need for outsourcing manufacturing capabilities in the pharmaceutical industry. The robust pipeline of peptide drugs in development, including both generic and novel entities, contributes to the growing demand for peptide API manufacturing services from CMOs. As more peptide drugs progress through clinical trials and regulatory approval processes, the demand for CMOs to manufacture these APIs is expected to increase.

View Full Report: https://www.precisionbusinessinsights.com/market-reports/global-peptide-api-cmo-market

THE PEPTIDE API CMO MARKET DETAILED SEGMENTATION:
Based on the product type, the market is segmented into the following:
• Peptide Generic API
• Peptide NCEs

Based on the product type, the global peptide API CMO market is segmented into peptide generic API, peptide NCEs. The peptide NCEs will account for 58.3% revenue share in 2023 and projected to grow at a notable CAGR of 6.8% to reach US$ 1,519.1 Mn by 2029. Peptide NCEs represent a significant area of innovation within the pharmaceutical industry, with companies investing in R&D to discover and develop new peptide drugs targeting various diseases. On the other hand, peptide generic APIs accounted for 41.7% revenue share in 2023, projected to grow at a higher CAGR of 7.7% to reach US$ 1,140.7 Mn by 2029.

Based on the therapeutic area, the market is segmented into the following:
• Oncology
• Cardiovascular Disorders
• Metabolic Disorders
• CNS Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Anti-infectives
• Dermatology
• Renal Disorders
• Others

Based on the therapeutic area, the global peptide API CMO market is segmented into oncology, cardiovascular disorders, metabolic disorders, CNS disorders, respiratory disorders, gastrointestinal disorders, anti-infectives, dermatology, renal disorders, others. The oncology segment will account for 25.8% revenue share in 2023. Projected to grow at a 4.0% CAGR from 2023 to 2029, oncology remains a leading therapeutic area due to the increasing demand for innovative cancer treatments and the robust pipeline of peptide-based drugs in various stages of clinical development. Additionally, the anti-infectives segment represents a lucrative market opportunity, driven by the global increase in antimicrobial resistance and the demand for novel therapies to combat infectious diseases.

Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=36185

Based on the end user, the market is segmented into the following:
• Pharmaceutical Companies
• Biopharmaceutical Companies

Based on the end user, the global Peptide API CMO Market is segmented into pharmaceutical companies, biopharmaceutical companies. Pharmaceutical companies accounted for 56.4% revenue share in 2023, projected to grow at a 6.7% CAGR to reach US$ 1,458.8 Mn by 2029. Biopharmaceutical companies accounted for 43.6% revenue share in 2023, projected to grow at a higher CAGR of 7.8% to reach US$ 1,210.0 Mn by 2029. This segment is expected to gain significant traction over the forecast period, driven by the rapid growth of the biopharmaceutical sector and increasing demand for peptide APIs.

Based on geography, the market is segmented into the following:
• North America
• Europe
• The Asia Pacific
• Latin America
• MEA

The North America peptide API CMO market is expected to increase over the forecast period due to the growing interest in personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic makeup, lifestyle, and environmental factors, is gaining traction in North America. Peptide therapeutics play a crucial role in personalized medicine due to their high specificity and targetability. As a result, there is a growing demand for peptide API CMOs to support the development and manufacturing of personalized peptide-based drugs. The increasing demand for personalized medicine in North America is driving pharmaceutical companies to collaborate with peptide API CMOs to develop customized peptide-based therapies tailored to individual patient profiles. Peptide API CMOs are investing in advanced technologies and manufacturing capabilities to meet the stringent requirements of personalized medicine, such as high purity and precise dosage formulations. In conclusion, the North America Peptide API CMO market is characterized by rapid growth in personalized medicine, driven by increasing demand for tailored peptide-based therapies.

Request Methodology: https://www.precisionbusinessinsights.com/request-methodology/?product_id=36185

Strategic Expansion, Mergers, Collaborations, and Agreements are the key Strategies Adopted by Market Players:
The market players in the peptide API CMO market adopt a combination of these strategies to stay competitive, drive growth, and capitalize on opportunities in the dynamic pharmaceutical landscape. Companies invest in expanding their capabilities to meet the growing demand for peptide APIs. This includes entering new areas of manufacturing, such as synthetic oligonucleotide manufacturing, as seen with CordenPharma, leveraging existing expertise and infrastructure for diversification. For instance,

In September 2023, CordenPharma, has made a significant stride in expanding its capabilities by announcing its entry into synthetic oligonucleotide manufacturing. Leveraging its decades of expertise in solid-phase peptide manufacturing and extensive downstream processing capacity, CordenPharma is strategically investing in a two-phase expansion at its facility in Colorado.

In May 2023, PolyPeptide, has entered into a strategic collaboration with Numaferm, a German biotech firm renowned for its expertise in process development and production of peptides and proteins.

The successful conclusion of "The 3rd China Polypeptide Industry Conference and the 2nd General Assembly of the Polypeptide Branch of China Biochemical Pharmaceutical Industry Association" in Shenzhen from September 20-22, 2023, marks a significant milestone for the peptide industry. Chinese Peptide company's invitation to attend the conference underscores its recognition and involvement in shaping the future of the polypeptide sector within China's biochemical pharmaceutical industry.

Key players profiles in the Peptide API CMO Market report are ScinoPharm Taiwan, Ltd. Corden Pharma International, Bachem AG, Biopeptek Pharmaceuticals LLC., Hybio Pharmaceutical Co., Ltd., Chinese Peptide Company, AmbioPharm, Inc., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Chemi S.p.A.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to delivering more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.